At a compression suite conditioned to 21°C ± 2°C and 35% RH ± 5%, adenosine 3',5'-cyclic monophosphate (cAMP) is screened through a 0.20 mm stainless-steel sieve and premixed with microcrystalline cellulose in a 1:5 w/w ratio using a bin blender operated at 12 rpm for 15 minutes. A representative enteric-coated tablet core comprises 10.0% w/w cAMP, 42.0% w/w microcrystalline cellulose, 30.0% w/w mannitol, 13.0% w/w lactose monohydrate, 3.5% w/w croscarmellose sodium, 0.8% w/w colloidal silicon dioxide, and 0.7% w/w magnesium stearate. The final blend is compressed on a 10-station instrumented rotary press using 9.5 mm round flat-faced bevel punches at 8–14 kN; tablets are measured for hardness 50–80 N and friability <0.5% w/w per USP <1216>. Enteric film coating is applied as an aqueous methacrylic acid-ethyl acrylate copolymer dispersion to a 8.0% w/w weight gain, using a pan coater with inlet temperature 45–50°C and pan speed 6–10 rpm. Acid-stage release in 0.1 N HCl for 2 hours remains below 10%, and buffered-stage release in 900 mL pH 6.8 phosphate buffer at 50 rpm with USP Apparatus 2 reaches Q=80% at 45 minutes. Content uniformity is assessed by USP <905> with an acceptance value not exceeding 15; loss on drying is controlled below 2.0% w/w by USP <731>. Process validation batches are executed under 21 CFR 211.110 and 21 CFR 211.165; the finished tablets are packed in HDPE bottles with induction-sealed closures and a desiccant when distribution climates exceed 60% RH.

Roller-Compacted Granulate for Hard Gelatin Capsule Filling

A dry granulation route is selected when the API particle size distribution shows a D90 below 45 µm and direct compression produces segregation in the feed frame. Adenosine 3',5'-cyclic monophosphate is blended with 13.3% w/w cAMP, 20.0% w/w pregelatinized starch, 35.0% w/w mannitol, 15.0% w/w microcrystalline cellulose, 5.0% w/w crospovidone, 0.5% w/w sodium stearyl fumarate, and 11.2% w/w lactose monohydrate prior to roller compaction. The blend is compacted on a roller compactor with 1.5 mm smooth rolls at 12 kN/cm roll force, 8 rpm roll speed, and 2.0 mm gap; ribbons are milled through an oscillating mill fitted with a 0.8 mm screen, yielding granulate with D50 180–250 µm and bulk density 0.45–0.55 g/mL. A 150 mg fill weight delivers 20 mg cAMP in a size 3 hard gelatin capsule; lubrication with 0.5% w/w sodium stearyl fumarate is performed in a bin blender at 10 rpm for 5 minutes. The granulate is filled on a dosator-type capsule machine with tamping pin settings at 3 mm intrusion and 6000 capsules/hour; in-process checks include weight variation not exceeding ±5.0% and disintegration in 900 mL pH 6.8 phosphate buffer. Capsule dissolution uses USP <711> Apparatus 1 at 100 rpm, with a Q value of 80% at 60 minutes; analytical release includes USP <905> acceptance value ≤15 and USP <921> Karl Fischer moisture <3.0% w/w. The terminal product is packed in PVC/PVDC/aluminium blisters to limit moisture ingress; stability chambers are set at 25°C/60% RH and 40°C/75% RH per ICH Q1A(R2).

What Final Granule Moisture Level Prevents Hydrolytic Degradation in Sachet Dosage Forms?

The limiting parameter in fluid-bed granulation is the final moisture content because residual water above 2.5% w/w accelerates hydrolysis to 5'-AMP during storage. A top-spray fluid-bed granulator with an 18-inch bowl is charged with a blend containing 1.0% w/w cAMP, 30.0% w/w mannitol, 25.0% w/w microcrystalline cellulose, 20.0% w/w lactose monohydrate, 10.0% w/w maize starch, 4.0% w/w povidone K30 in the granulating fluid, 8.0% w/w crospovidone, and 2.0% w/w colloidal silicon dioxide. The binder solution is sprayed at 8–12 g/min with an inlet air temperature of 65°C ± 5°C, product temperature 28–32°C, atomizing air pressure 1.5 bar, and bed dew point below 6°C. Granules are dried to a loss on drying of 1.5–2.0% w/w by USP <731>, milled through a 0.5 mm screen, and filled into foil sachets at 2.0 g per unit to deliver 20 mg cAMP. Sachet reconstitution in 50 mL water at 25°C produces a clear dispersion within 30 seconds; osmolality is measured with a freezing-point osmometer and controlled between 250–350 mOsm/kg. Dissolution of the reconstituted granule is tested in 900 mL pH 6.8 phosphate buffer with USP Apparatus 2 at 50 rpm; the release specification is Q=80% at 30 minutes. Microbial quality of the non-sterile product is set at total aerobic microbial count ≤10³ CFU/g and total combined yeasts and molds ≤10² CFU/g per USP <61>; absence of Escherichia coli is confirmed per USP <62>. The sachet product is labeled as granules for oral solution; package desiccant is not required when the foil laminate has an aluminium thickness of 9 µm.

For freeze-dried vials, a bulk solution is compounded by dissolving adenosine 3',5'-cyclic monophosphate in Water for Injection at 2–8°C to a concentration of 10.0 mg/mL, followed by addition of 40.0 mg/mL mannitol as a crystallizing bulking agent. The solution pH is adjusted to 6.2–6.8 with 0.1 N sodium hydroxide or hydrochloric acid, then sterile-filtered through a 0.22 µm polyethersulfone membrane at 20–25°C under nitrogen pressure below 1.0 bar. The filtered solution is filled into Type I glass vials at 2.0 mL per vial, partially stoppered with bromobutyl lyophilization closures, and loaded onto lyophilizer shelves prechilled to 5°C. The lyophilization cycle freezes to −40°C at 0.5°C/min and holds for 2 hours; primary drying is controlled at shelf temperature −15°C and chamber pressure 150 mTorr for 18 hours; secondary drying raises shelf temperature to 35°C at 0.2°C/min with chamber pressure 50 mTorr for 6 hours. Cake temperature must remain below the collapse temperature; collapse is detected by product thermocouples and comparative manometric measurement. Residual moisture is determined by USP <921> Karl Fischer and is limited to <1.0% w/w; reconstitution time with 2.0 mL Water for Injection at 20–25°C is <90 seconds. The freeze-dried vial is tested for particulate matter per USP <788>: not more than 6000 particles ≥10 µm per container and 600 particles ≥25 µm per container. Bacterial endotoxin limit is calculated per USP <85>; using K = 5 EU/kg and a maximum single dose of 20 mg in a 70 kg patient, the limit is 17.5 EU/mg of cAMP, equivalent to 350 EU/vial. Sterility testing follows USP <71> with direct inoculation and membrane filtration. The terminal vial contains 20 mg cAMP for injection and is stored at 2–8°C; the stopper is secured with an aluminium flip-off seal and the product is labeled for single-dose intravenous administration after reconstitution.

When the Meglumine Salt Is Chosen for Aqueous Injectable Solutions

Conversion to the meglumine salt is performed in a closed stainless-steel reactor under nitrogen because the free phosphate diester requires pH control and is susceptible to oxidative discoloration. A 1.0:1.0 molar ratio of adenosine 3',5'-cyclic monophosphate to meglumine is dissolved in Water for Injection at 20–25°C; the resulting solution is adjusted to pH 6.2–6.8 with 0.1 N hydrochloric acid or sodium hydroxide and made to volume with WFI to achieve an API concentration of 10.0 mg/mL as cAMP base. The solution is sparged with nitrogen to dissolved oxygen below 2 ppm and passed through a 0.45 µm polypropylene prefilter followed by two 0.22 µm PVDF membrane filters in series. Aseptic filling proceeds on a rotary piston pump line into 2 mL Type I glass ampoules under Grade A air supply with Grade B background per ISO 14644-1:2015 and EU GMP Annex 1. Fill volume is controlled to 2.15 mL ± 0.02 mL; bubble-point testing of the sterilizing filter is performed before and after filling per 21 CFR 211.84. Iron and aluminum extractables from glass are controlled because trace cations catalyze phosphate ester hydrolysis; the finished solution is stored at 2–8°C and protected from light. Release testing includes pH 6.2–6.8, osmolality 250–350 mOsm/kg, particulate matter USP <788>, sterility USP <71>, and bacterial endotoxins per USP <85>. The terminal product is a ready-to-use injectable solution containing 20 mg cAMP per 2 mL ampoule; it is used only after visual inspection for glass particles and leakers.

On a multi-particulate capsule line, the API is dispersed in a dry blend containing 10.0% w/w cAMP, 55.0% w/w microcrystalline cellulose, and 35.0% w/w lactose monohydrate; purified water is added at 30.0% w/w of the dry mass in a planetary mixer. The wet mass is extruded through a 0.8 mm screen at screw speed 40 rpm, spheronized at 900 rpm for 5 minutes, and dried in a fluid bed at 60°C to a loss on drying below 2.0% w/w; pellets with a diameter of 0.8–1.0 mm are retained. Enteric coating is applied in a Wurster column using an aqueous methacrylic acid-ethyl acrylate copolymer dispersion to a 20.0% w/w polymer weight gain, with triethyl citrate at 10.0% w/w of polymer solids and talc at 50.0% w/w of polymer solids. The coated pellets are filled into size 1 hard gelatin capsules at a fill weight of 240 mg, delivering 20 mg cAMP per capsule. Acid-stage dissolution in 0.1 N HCl for 2 hours shows individual unit release below 10%; buffered-stage dissolution in 900 mL pH 6.8 phosphate buffer at 75 rpm with USP Apparatus 1 reaches Q=80% at 45 minutes. Content uniformity is assessed by USP <905> with an acceptance value ≤15, and pellet friability is monitored by sieve retention after 10 minutes of stress. The terminal capsule is packaged in aluminium/aluminium blisters with a cold-forming foil; moisture uptake after 6 months at 25°C/60% RH is controlled below 0.5% w/w.